Investors & Media

Webcast ImageWebcast
Isis Pharmaceuticals’ Annual Stockholder Meeting (Replay)
06/30/15 at 2:00 p.m. PT
Isis Pharmaceuticals’ Annual Stockholder Meeting
Tuesday, June 30, 2015 2:00 p.m. PT  through Tuesday, June 30, 2015 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The efficiency of our drug discovery technology allows us to employ a unique business strategy designed to maximize the value of our drugs and technology while maintaining an effective cost structure that limits our cash needs. Our business strategy is supported by our platform technology, our robust pipeline of drugs and our multifaceted partnering strategy, which have enabled us to focus on doing what we do best - to discover and develop novel antisense drugs.
Recent Press ReleasesMore >>
06/30/15Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting
CARLSBAD, Calif., June 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:   Corporate presentation at its 2015 Annual Meeting of Stockholders When:     Tuesday, June 30 at 5:10 p.m. ET / 2:10 p.m. PT Where:  How:        Live on the Internet.  Simply log onto our website listed above. ... 
Printer Friendly Version
06/29/15Isis Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index
CARLSBAD, Calif., June 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has been added to the Russell 1000 Index, effective June 26, 2015. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership. "We are pleased to be added to this impo... 
Printer Friendly Version
06/22/15Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Continued increases observed in multiple measures of muscle function in SMA children treated with ISIS-SMN Rx CARLSBAD, Calif., June 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx  and are continuing to receive treatment in an open-label extension (OLE) study.  Consistent with earlier observations, increases in muscle function... 
Printer Friendly Version
06/16/15Isis Pharmaceuticals to Present a General Corporate Update at its 2015 Annual Meeting of Stockholders and Open House
CARLSBAD, Calif., June 16, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2015 Annual Meeting of Stockholders and Open House on Tuesday, June 30 at 2:10 p.m. Pacific Time in Carlsbad, CA. The agenda for the meeting is as follows: 2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of record as of May 4, 2015) 2:10 p.... 
Printer Friendly Version
Upcoming EventsMore >>
2015 Peripheral Nerve Society Meeting
LocationQuebec City, QuebecCA
Nucleosides, Nucleotides & Oligonucleotides, Gordon Research Conference
LocationNewport, RI

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.